Ключевые слова
Как цитировать
Аннотация
Гормоночувствительный рак молочной железы (РМЖ) является распространённым типом злокачественного новообразования. Его терапия подразумевает назначение гормонотерапии, которая зачастую осложняется развитием боли в суставах. Причина развития артралгий у таких больных до сих пор неясна, однако имеются основания полагать, что они могут носить воспалительный характер. В статье представлено текущее понимание данной проблемы, а также возможные патофизиологические аспекты развития аутоиммунной и аутовоспалительной патологии у пациенток, получающих эстроген-депривационную терапию РМЖ.
Библиографические ссылки
Sung H., Ferlay J., Siegel R.L., et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021; 71(3): 209-249.-DOI: https://doi.org/10.3322/caac.21660.
Мерабишвили В.М. Состояние онкологической помощи в России: рак молочной железы среди женского населения. Заболеваемость, смертность, достоверность учета, детальная локализационная и гистологическая структура. (Популяционное исследование на уровне федерального округа). Вопросы онкологии. 2022; 68(3): 286-293.-DOI: https://doi.org/10.37469/0507-3758-2022-68-3-286-293. URL: https://voprosyonkologii.ru/index.php/journal/article/view/1373.
[Merabishvili V.M. The state of cancer care In Russia: breast cancer among the female population. Morbidity, mortality, index of accuracy, detailed localization and histological structure. (Population study at the federal district level). Voprosy Onkologii = Problems in Oncology. 2022; 68(3): 286-293.-DOI: https://doi.org/10.37469/0507-3758-2022-68-3-286-293. URL: https://voprosyonkologii.ru/index.php/journal/article/view/1373. (In Rus)].
Howlader N., Altekruse S.F., Li C.I., et al. US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status. J Natl Cancer Inst. 2014; 106(5): dju055.-DOI: https://doi.org/10.1093/jnci/dju055.
Cardoso F., Senkus E., Costa A., et al. 4th ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4). Ann Oncol. 2018; 29(8): 1634-57.-DOI: https://doi.org/10.1093/annonc/mdy192.
Кононенко И.Б., Снеговой А.В., Гребенникова О.П., и др. Побочные эффекты адъювантной гормонотерапии. Медицинский совет. 2018; (10): 64-69.-DOI: https://doi.org/10.21518/2079-701X-2018-10-64-69.
[Kononenko I.B., Snegovoi AV, Grebennikova O.P., et al. Adverse effects of adjuvant endocrine therapy. Meditsinskiy sovet = Medical Council. 2018; (10): 64-69.-DOI: https://doi.org/10.21518/2079-701X-2018-10-64-69. (In Rus)].
Beckwée D., Leysen L., Meuwis K., Adriaenssens N. Prevalence of aromatase inhibitor-induced arthralgia in breast cancer: a systematic review and meta-analysis. Support Care Cancer. 2017; 25(5): 1673-86.-DOI: https://doi.org/10.1007/s00520-017-3613-z.
Rangel-Méndez J.A., Rubi-Castellanos R., Sánchez-Cruz J.F., Moo-Puc R.E. Tamoxifen side effects: pharmacogenetic and clinical approach in Mexican mestizos. Transl Cancer Res. 2019; 8(1): 23-34.-DOI: https://doi.org/10.21037/tcr.2018.12.27.
Friedman A.J., Juneau-Norcross M., Rein M.S. Adverse effects of leuprolide acetate depot treatment. Fertil Steril. 1993; 59(2): 448-50.-DOI: https://doi.org/10.1016/s0015-0282(16)55701-x.
Owens C., Andelkovic V., Pathmanathan S., et al. Early discontinuation rates of aromatase inhibitors due to musculoskeletal side effects. Breast Cancer Management. 2016: 5(1);13-20.-DOI: https://doi.org/10.2217/bmt.15.29.
Henry N.L., Azzouz F., Desta Z., et al. Predictors of aromatase inhibitor discontinuation as a result of treatment-emergent symptoms in early-stage breast cancer. J Clin Oncol. 2012; 30: 936-42.-DOI: https://doi.org/10.1200/JCO.2011.38.0261.
Wendling D., Letho-Gyselinck H., Guillot X., et al. Arthralgia and aromatase inhibitors. Joint Bone Spine. 2014; 81(2): 187-8.-DOI: https://doi.org/10.1016/j.jbspin.2013.06.011.
Chim K., Xie S.X., Stricker C.T., et al. Joint pain severity predicts premature discontinuation of aromatase inhibitors in breast cancer survivors. BMC Cancer. 2013; 13: 401.-DOI: https://doi.org/10.1186/1471-2407-13-401.
Hershman D.L., Shao T., Kushi L.H., et al. Early discontinuation and non-adherence to adjuvant hormonal therapy are associated with increased mortality in women with breast cancer. Breast Cancer Res Treat. 2011; 126(2): 529-37.-DOI: https://doi.org/10.1007/s10549-010-1132-4.
Donnellan P.P., Douglas S.L., Cameron D.A., Leonard R.C. Aromatase inhibitors and arthralgia. J Clin Oncol. 2001; 19(10): 2767.
Moxley G. Rheumatic disorders and functional disability with aromatase inhibitor therapy. Clin Breast Cancer. 2010; 10(2): 144-7.-DOI: https://doi.org/10.3816/CBC.2010.n.019.
Henry N.L., Giles J.T., Ang D., et al. Prospective characterization of musculoskeletal symptoms in early stage breast cancer patients treated with aromatase inhibitors. Breast Cancer Res Treat. 2008; 111(2): 365-72.-DOI: https://doi.org/10.1007/s10549-007-9774-6.
Lintermans A., Laenen A., Van Calster B., et al. Prospective study to assess fluid accumulation and tenosynovial changes in the aromatase inhibitor-induced musculoskeletal syndrome: 2-year follow-up data. Ann Oncol. 2013; 24(2): 350-5.-DOI: https://doi.org/10.1093/annonc/mds290.
Shin D.J., Nam K.E., Song D.H., et al. Carpal tunnel syndrome and tenosynovitis in women with breast cancer associated with hormone therapy: A multi-institutional analysis using a clinical data warehouse. Medicine (Baltimore). 2022; 101(5): e28786.-DOI: https://doi.org/10.1097/MD.0000000000028786.
Morales L., Pans S., Paridaens R., et al. Debilitating musculoskeletal pain and stiffness with letrozole and exemestane: associated tenosynovial changes on magnetic resonance imaging. Breast Cancer Res Treat. 2007; 104(1): 87-91.-DOI: https://doi.org/10.1007/s10549-006-9394-6.
Scarpa R., Atteno M., Peluso R., et al. Rheumatic complaints in women taking aromatase inhibitors for treatment of hormone-dependent breast cancer. J Clin Rheumatol. 2011; 17(4): 169-72.-DOI: https://doi.org/10.1097/RHU.0b013e31821bfc48.
Laroche M., Borg S., Lassoued S., et al. Joint pain with aromatase inhibitors: abnormal frequency of Sjögren's syndrome. J Rheumatol. 2007; 34(11): 2259-63.
Laroche M., Seniow M., Roché H., et al. Arthralgia associated with autoimmune abnormalities under aromatase inhibitor therapy: outcome after cessation of treatment. J Rheumatol. 2016; 43(10): 1945-6.-DOI: https://doi.org/10.3899/jrheum.160254.
Chen J.Y., Ballou S.P. The effect of antiestrogen agents on risk of autoimmune disorders in patients with breast cancer. J Rheumatol. 2015; 42(1): 55-9.-DOI: https://doi.org/10.3899/jrheum.140367.
Caprioli M., Carrara G., Sakellariou G., et al. Influence of aromatase inhibitors therapy on the occurrence of rheumatoid arthritis in women with breast cancer: results from a large population-based study of the Italian Society for Rheumatology. RMD Open. 2017; 3(2): e000523.-DOI: https://doi.org/10.1136/rmdopen-2017-000523.
Chien H.C., Kao Yang Y.H., Kwoh C.K., et al. Aromatase Inhibitors and Risk of Arthritis and Carpal Tunnel Syndrome among Taiwanese Women with Breast Cancer: A Nationwide Claims Data Analysis. J Clin Med. 2020; 9(2): 566.-DOI: https://doi.org/10.3390/jcm9020566
Колтакова А.Д., Лила А.М., Алексеева О.Г. Ревматические аспекты артралгий, ассоциированных с терапией ингибиторами ароматазы (анализ серии клинических случаев). Современная ревматология. 2023; 17(1): 51-7.-DOI: https://doi.org/10.14412/1996-7012-2023-1-51-57.
[Koltakova A.D., Lila A.M., Alekseeva O.G. Rheumatic aspects of arthralgias associated with aromatase inhibitor therapy (analysis of a clinical case series). Sovremennaya Revmatologiya = Modern Rheumatology Journal. 2023; 17(1): 51-57.-DOI: https://doi.org/10.14412/1996-7012-2023-1-51-57. (In Rus)].
Szoeke C.E., Cicuttini F.M., Guthrie J.R., et al. The relationship of reports of aches and joint pains to the menopausal transition: a longitudinal study. Climacteric. 2008; 11(1): 55-62.-DOI: https://doi.org/10.1080/13697130701746006.
Goemaere S., Ackerman C., Goethals K., et al. Onset of symptoms of rheumatoid arthritis in relation to age, sex and menopausal transition. J Rheumatol. 1990; 17(12): 1620-2.
Cecil R.L., Archer B.H. Arthritis of the menopause: a study of fifty cases. J Am Med Assoc. 1925; 84: 75-9.-DOI: https://doi.org/10.1001/jama.1925.02660280001001.
Magliano M. Menopausal arthralgia: Fact or fiction. Maturitas. 2010; 67(1): 29-33.-DOI: https://doi.org/10.1016/j.maturitas.2010.04.009.
Cutolo M., Accardo S., Villaggio B., et al. Presence of estrogen-binding sites on macrophage-like synoviocytes and CD8+, CD29+, CD45RO+ T lymphocytes in normal and rheumatoid synovium. Arthritis Rheum. 1993; 36(8): 1087-97.-DOI: https://doi.org/10.1002/art.1780360809.
Richmond R.S., Carlson C.S., Register T.C., et al. Functional estrogen receptors in adult articular cartilage: estrogen replacement therapy increases chondrocyte synthesis of proteoglycans and insulin-like growth factor binding protein 2. Arthritis Rheum. 2000; 43(9): 2081-90.-DOI: https://doi.org/10.1002/1529-0131(200009)43:9<2081::AID-ANR20>3.0.CO;2-I.
Chen X., Cai C., Liu J., et al. Impact of estrogen-related receptor α on the biological characteristics of rat mandibular condylar chondrocytes. Mol Med Rep. 2014; 10(1): 195-202.-DOI: https://doi.org/10.3892/mmr.2014.2210.
Nalbandian G., Kovats S. Estrogen, immunity & autoimmune disease. Curr Med Chem – Immun, Endoc & Metab Agents. 2005; 5: 85-91.-DOI: https://doi.org/10.2174/1568013053005418.
Straub R.H. The complex role of estrogens in inflammation. Endocr Rev. 2007; 28(5): 521-74.-DOI: https://doi.org/10.1210/er.2007-0001.
Josefsson E., Tarkowski A. Suppression of type II collageninduced arthritis by the endogenous estrogen metabolite 2-methoxyestradiol. Arthritis Rheum. 1997; 40(1): 154-63.-DOI: https://doi.org/10.1002/art.1780400120.
Wang J.X., Zhang Q.Y., Jin S., et al. Genistein modulate immune responses in collagen-induced rheumatoid arthritis model. Maturitas. 2008; 59(4): 405-12.-DOI: https://doi.org/10.1016/j.maturitas.2008.04.003.
Jeong H., Bae E.K., Kim H., et al. Estrogen attenuates the spondyloarthritis manifestations of the SKG arthritis model. Arthritis Res Ther. 2017; 19(1): 198.-DOI: https://doi.org/10.1186/s13075-017-1407-9.
Liu Y.P., Li J., Xin S.B., X J. Study the relevance between inflammatory factors and estradiol and their association with knee osteoarthritis in postmenopausal women. Eur Rev Med Pharmacol Sci. 2018; 22(2): 472-478.-DOI: https://doi.org/10.26355/eurrev_201801_14197.
Vural P., Canbaz M., Akgul C. Effects of menopause and postmenopausal tibolone treatment on plasma TNFalpha, IL-4, IL-10, IL-12 cytokine pattern and some bone turnover markers. Pharmacol Res. 2006; 53(4): 367-71.-DOI: https://doi.org/10.1016/j.phrs.2006.01.005.
Afzal S., Khanam A. Serum estrogen and interleukin-6 levels in postmenopausal female osteoarthritis patients. Pak J Pharm Sci. 2011; 24: 217-9.
Saito S., Aras R.S., Lou H., et al. Effects of estrogen on nitric oxide synthase expression in rat aorta allograft and smooth muscle cells. J Heart Lung Transplant. 1999; 18(10): 937-45.-DOI: https://doi.org/10.1016/s1053-2498(99)00060-1.
Huang N., Wang C., Zhang N., et al. Effect of estrogen on prostaglandin synthetase in bovine oviduct smooth muscle. Eur J Pharmacol. 2018; 818: 287-93.-DOI: https://doi.org/10.1016/j.ejphar.2017.10.058.
Jung J.H., Bang C.H., Song G.G., et al. Knee osteoarthritis and menopausal hormone therapy in postmenopausal women: a nationwide cross-sectional study. Menopause. 2018; 26(6): 598-602.-DOI: https://doi.org/10.1097/GME.0000000000001280.
Xiao Y.P., Tian F.M., Dai M.W., et al. Are estrogen-related drugs new alternatives for the management of osteoarthritis? Arthritis Res Ther. 2016; 18: 151.-DOI: https://doi.org/10.1186/s13075-016-1045-7.
Jimenez-Balderas F.J., Tapia-Serrano R., Madero-Cervera J.I., et al. Ovarian function studies in active ankylosing spondylitis in women. Clinical response to estrogen therapy. J Rheumatol. 1990; 17(4): 497-502.
Cortés M., Canellada A., Miranda S., et al. Placental secreted factors: their role in the regulation of anti-CII antibodies and amelioration of collagen induced arthritis in rats. Immunol Lett. 2008; 119(1-2): 42-8.-DOI: https://doi.org/10.1016/j.imlet.2008.04.001.
Jingxuan W., Qingyuan Z., Shi J., et al. Immoderate inhibition of estrogen by anastrozole enhances the severity of experimental polyarthritis. Experimental Gerontology. Exp Gerontol. 2009; 44(6-7): 398-405.-DOI: https://doi.org/10.1016/j.exger.2009.03.003.
Watson W.C., Townes A.S. Genetic susceptibility to murine collagen II autoimmune arthritis. Proposed relationship to the IgG2 autoantibody subclass response, complement C5, major histocompatibility complex (MHC) and nonMHC loci. J Exp Med. 1985; 162(6): 1878-9.-DOI: https://doi.org/10.1084/jem.162.6.1878.
Zhao J., Li R., He J., et al. Mucosal administration of an altered CII263–272 peptide inhibits collagen-induced arthritis by suppression of Th1/Th17 cells and expansion of regulatory T cells. Rheumatol Int. 2008; 29(1): 9-16.-DOI: https://doi.org/10.1007/s00296-008-0634-4.
Young N.A., Hampton J., Sharma J., et al. Aromatase inhibitor induced musculoskeletal inflammation is observed independent of oophorectomy in a novel mouse model. BioRxiv. 2022.-DOI: https://doi.org/10.1101/2022.06.22.497263.
Young N.A., Hampton J., Sharma J., et al. Aromatase-inhibitor-induced musculoskeletal inflammation is observed independent of oophorectomy in a novel mouse model. Pharmaceuticals (Basel). 2022; 15(12): 1578.-DOI: https://doi.org/10.3390/ph15121578.
Shim G.J., Warner M., Kim H.J., et al. Aromatase-deficient mice spontaneously develop a lymphoproliferative autoimmune disease resembling Sjogren's syndrome. Proc Natl Acad Sci USA. 2004: 101(34): 12628-33.-DOI: https://doi.org/10.1073/pnas.0405099101.
Iwasa A., Arakaki R., Honma N., et al. Aromatase controls Sjögren syndrome-like lesions through monocyte chemotactic protein-1 in target organ and adipose tissue-associated macrophages. Am J Pathol. 2015; 185(1): 151-61.-DOI: https://doi.org/10.1016/j.ajpath.2014.09.006.
Fuentes N., Silveyra P. Estrogen receptor signaling mechanisms. Adv Protein Chem Struct Biol. 2019; 116: 135-70.-DOI: https://doi.org/10.1016/bs.apcsb.2019.01.001.
Sthoeger Z.M., Zinger H., Mozes E. Beneficial effects of the anti-oestrogen tamoxifen on systemic lupus erythematosus of (NZBxNZW)F1 female mice are associated with specific reduction of IgG3 autoantibodies. Ann Rheum Dis. 2003; 62(4): 341-6.-DOI: https://doi.org/10.1136/ard.62.4.341.
Sturgess A.D., Evans D.T., Mackay I.R., Riglar A. Effects of the oestrogen antagonist tamoxifen on disease indices in systemic lupus erythematosus. J Clin Lab Immunol. 1984; 13(1): 11-4.
Mohammed E.A., Sharief N., Abukashawa S., et al., Tamoxifen-induced lupus erythematosus. J Drug Metab Toxicol. 2013; 4: 1.-DOI: https://doi.org/10.4172/2157-7609.1000138.
Это произведение доступно по лицензии Creative Commons «Attribution-NonCommercial-NoDerivatives» («Атрибуция — Некоммерческое использование — Без производных произведений») 4.0 Всемирная.
© АННМО «Вопросы онкологии», Copyright (c) 2024